INTRODUCTION

Antibodies, passively administered to animals or humans, can have profound effects on the immune response to their specific antigen. When preformed antibodies are co-administered with the antigen they recognize, antibody responses can be enhanced more than a 100-fold or suppressed more than 99% as compared to responses in animals immunized with antigen alone (reviewed in Refs1-4). The earliest studies on how antibodies regulate antibody responses were performed in relation to serum therapy against diphtheria in the end of the 19th century. It was of utmost importance to produce high titre anti-diphtheria toxin to use for treating diphtheria patients. Emil von Behring and coworkers found that immunizing animals with mixtures of antiserum and diphtheria toxin, instead of toxin alone, resulted in production of high titre sera while the toxic effects could be prevented.5,6 This early observation illustrates the balance between the ability of antibodies to upregulate a response to a protein, for example diphtheria toxin, while at the same time neutralizing its effects. Scandinavian immunologists showed an early interest in antibody feedback regulation with Göran Möller and Hans Wigzell studying the suppressive effects on responses...
to sheep red blood cells (SRBC) in the 1960s.\textsuperscript{7,8} It soon became clear that the suppressive effect in SRBC-specific sera was found in the 7S fraction (IgG) and the enhancing effect in the 19S fraction (IgM).\textsuperscript{9}

In the following decades, using monoclonal antibodies and gene-targeted mice, the mechanisms behind the enhancing effects of different antibody isotypes were studied in detail. We now know that IgM enhances via the complement system,\textsuperscript{10,11} primarily by increasing the amount of antigen localized on follicular dendritic cells.\textsuperscript{12,13} IgE enhances antibody and T-cell responses to small proteins by forming an immune complex which binds to the low-affinity receptor for IgE (CD23) on circulating B cells.\textsuperscript{14} These B cells have access to the splenic B-cell follicles and substantial amounts of antigen can be detected there 30 minutes after immunization with IgE and antigen.\textsuperscript{14,15} The antigen is subsequently presented to CD4+ T helper cells which become activated and proliferate.\textsuperscript{15,17} Presumably, their efficient interaction with cognate B cells leads to the enhanced antibody responses first observed.\textsuperscript{18,19} The cells presenting IgE-antigen to T helper cells are dendritic cells\textsuperscript{15,20} and not B cells which were initially assumed. Murine dendritic cells do not express CD23\textsuperscript{15} and therefore CD23+ B cells must somehow deliver IgE antigen to them, but exactly how this transfer takes place is not yet understood.

IgG antibodies, either passively administered or actively produced, can suppress the antibody response against the antigen they recognize. In a clinical setting, maternal antibodies inhibit infant antibody responses against many vaccines, such as tetanus, diphtheria, pertussis and hepatitis A (reviewed in Ref\textsuperscript{21}). The ability of passively administered IgG to suppress antibody responses to erythrocytes has been used successfully in the clinic. Administration of IgG anti-Rhesus (Rh)D to RhD-negative women, at risk of becoming sensitized against RhD-positive foetal erythrocytes following transplacental haemorrhage, has proven very efficient in preventing haemolytic disease of the foetus and newborn.\textsuperscript{22,23} In animals, IgG can suppress responses to proteins administered in adjuvants\textsuperscript{24} or in physiological salt solutions,\textsuperscript{25,26} as well as to viruses.\textsuperscript{27,28} However, the vast majority of studies of IgG-mediated immune suppression have been performed using erythrocytes as antigens and this will be discussed in detail below.

In addition to suppressing antibody responses to, for example, erythrocytes, IgG antibodies of all subclasses can enhance antibody- and T helper cell responses to proteins.\textsuperscript{25,29,30} In analogy with IgM, murine IgG3 operates via complement\textsuperscript{31} and the mechanism seems to be that marginal zone B cells, which express complement receptors 1 and 2 (CR1/CR2), transport IgG3-antigen-complement complexes to follicular dendritic cells.\textsuperscript{32,33} IgG1, IgG2a and IgG2b are dependent on activating FcγRs for their enhancing effects\textsuperscript{29,30,34,35} and most likely operate by increasing uptake of IgG-antigen by FcγR\textsuperscript{7} dendritic cells for processing and presentation of antigenic peptides to T helper cells.\textsuperscript{35}

The focus of this review will be on the ability of IgG antibodies to suppress antibody responses in vivo, primarily in mice. The experimental findings will first be presented and subsequently discussed in relation to the major hypotheses proposed to explain the phenomenon:

1. Central inhibition of B-cell activation through co-cross-linking of the B-cell receptor (BCR) with the negatively regulating FcγRIIB by IgG-antigen complexes.
2. Complement-mediated lysis of red blood cells.
3. Elimination/clearance of IgG-antigen complexes before they can stimulate an immune response.
4. Masking of epitopes on the antigen, preventing B cells from binding and becoming activated.
5. Trogocytosis/modulation leading to loss of IgG-bound epitopes, preventing B cells from binding and becoming activated.

### 2 WHICH TYPES OF RESPONSES ARE SUPPRESSED BY IgG?

IgG can suppress antibody responses to proteins\textsuperscript{25,26} and viruses,\textsuperscript{27,28} but most of our knowledge about the mechanism behind suppression comes from studies using erythrocytes. SRBC or SRBC conjugated to haptens such as trinitrophenyl (TNP) or 4-hydroxy-3-nitrophenylacetyl (NP) has frequently been used.\textsuperscript{7,9,36-42} More recently, murine transgenic erythrocytes expressing the entire human KEL glycoprotein (KEL-RBC),\textsuperscript{43,44} hen egg lysozyme in sequence with ovalbumin (OVA) and the complete human Duffy\textsuperscript{b} transmembrane protein (HOD-RBC),\textsuperscript{45-49} or both HOD and KEL antigens\textsuperscript{50} were used as antigen.

Many studies of IgG-mediated suppression in mice were performed with Jerne’s direct haemolytic plaque forming cell assay, detecting single IgM anti-SRBC-producing cells.\textsuperscript{51} With this sensitive method, it was shown that 90%-99% of the IgM responses could be suppressed\textsuperscript{9,36-38,52,53} (Figure 1). More recently, splenic germinal centre B cells as well as IgG-producing long-lived plasma cells in the bone-marrow were shown to be suppressed.\textsuperscript{50} Also primary serum IgM and IgG responses to xenogeneic\textsuperscript{39-41,54} as well as to allogeneic\textsuperscript{43-50} erythrocytes are suppressed by IgG.

IgG-mediated suppression is dose dependent: high doses of IgG suppress better than low doses and responses to high doses of antigen are more difficult to suppress than responses to low doses.\textsuperscript{9,37,38} Possibly, this explains why secondary antibody responses appear to be more difficult to inhibit than primary responses.\textsuperscript{52,55,56} In mice in which IgG suppressed the primary responses, memory/recall responses after boost with antigen alone were also suppressed but not always as...
efficiently as the primary response. In a recent study, the same relative suppression of primary and recall responses was observed in mice primed with IgG anti-SRBC and SRBC and boosted with SRBC 70 days later. This implies that the induction of memory cells and plasma cells was equally well suppressed during priming.

IgG only marginally, if at all, suppresses T helper cell responses in mice in which the antibody responses to SRBC are efficiently suppressed. In line with this, virus-specific antibodies inhibit the antibody- but not the T-cell responses against viruses in mice and humans. In summary, IgG suppresses both primary and secondary antibody responses and induction of immunological memory, but does not significantly suppress induction of T helper cells.

3 | WHAT TYPES OF ANTIBODIES CAN SUPPRESS?

Studies using monoclonal IgG antibodies have shown that all murine subclasses are able to suppress. Notably, this includes IgG3 which does not bind to the inhibitory FcγRIIB.

Although IgM usually enhances antibody responses to erythrocytes, suppression has occasionally been demonstrated. In the latter study, IgM had a dual effect and enhanced when administered before SRBC, but suppressed when given 2-48 hours after the antigen. This observation is compatible with the finding that IgM enhances by increasing the antigen concentration on follicular dendritic cells.

As mentioned in the Introduction, IgE administered with small proteins can enhance antibody responses via CD23. However, monoclonal IgE anti-TNP administered with SRBC-TNP, which is a large antigen, suppressed the antibody response equally well as did monoclonal IgG anti-TNP. IgE binds to the low-affinity receptor FcεRII (CD23), the high affinity FcεRI as well as to some Fc receptors for IgG (FcγRIIB, FcγRIII and FcγRIV). Because IgE-mediated suppression works well in mice lacking these receptors, it is unlikely that it is mediated via Fc receptors.

A unanimous finding is that high affinity IgG suppresses more efficiently than low-affinity IgG. Primary and secondary IgG suppresses equally well in relation to their ability to bind to SRBC in an enzyme-linked immunosorbent assay (ELISA), implying that the amount of IgG attached to the antigen, rather than the affinity per se, determines the suppressive capacity.

In summary, all murine subclasses are suppressive and high affinity IgG is more efficient than low-affinity IgG. The ability to suppress erythrocyte responses is not a unique feature of IgG antibodies although they are probably the most important ones owing to high affinity, high concentrations and long serum half life. The vast majority of our knowledge about antibody-mediated immune suppression stems from studies of IgG.

4 | CAN F(ab′)2 FRAGMENTS SUPPRESS?

Of crucial importance to understand the mechanism underlying IgG-mediated suppression is to determine whether it is dependent on the Fc region of IgG or not. Several laboratories have tested whether F(ab′)2 fragments can suppress, but results have been conflicting. Some investigators found that F(ab′)2 fragments do suppress and others that they do not. An inherent difficulty with these experiments is that F(ab′)2 fragments are eliminated faster than intact IgG owing to lack of binding to the neonatal FcR (FcRn) known to protect IgG from proteolysis. However, the reason for the discrepancies has not yet been clarified.

5 | WHEN MUST IgG BE ADMINISTERED IN RELATION TO ANTIGEN IN ORDER TO SUPPRESS?

In most experimental systems in which immunosuppression is studied, IgG is administered one or a few hours before the antigen. However, there are many examples of
efficient suppression also when IgG is administered after the antigen. In Rhesus prophylaxis, anti-D administered to the mother 72 hours after delivery of the baby, works well. In animal models, IgG can inhibit an ongoing antibody response as demonstrated by studying single cells producing IgM anti-SRBC. For example, IgG administered 1-6 days after SRBC suppressed the direct plaque forming cell (PFC) response 11 days after immunization with SRBC, that is after having interacted with the antigen during 5-10 days. In another experimental setup, IgG administered 2-4 days after SRBC suppressed the PFC response 7 days after immunization with SRBC, with 3-5 days of interaction. Also antibody responses to bacteriophages and KLH can be inhibited by IgG administered 1-3 days after immunization with antigen. These observations suggest that the antigen must continuously interact with the immune system in order for a sustained IgM response to take place. Possibly, passively administered IgG interferes with this interaction and terminates the antibody response.

6 | IS IgG-MEDIATED SUPPRESSION DEPENDENT ON FcγRs?

Because of the discrepant results regarding the ability of F(ab')2 fragments to suppress, it was of interest to determine Fc dependence with alternative methods. Using various Fc receptor for IgG (FcγR)-deficient mice, several laboratories have reported that IgG suppresses efficiently in mice lacking the activating receptors FcγRI, FcγRIII, and FcγRIV (owing to lack of the common Fc receptor gamma chain, FcγRγ) or the inhibitory FcγRIIB. For example, IgG administered 1-6 days after SRBC suppressed the direct plaque forming cell (PFC) response 11 days after immunization with SRBC, that is after having interacted with the antigen during 5-10 days. In another experimental setup, IgG administered 2-4 days after SRBC suppressed the PFC response 7 days after immunization with SRBC, with 3-5 days of interaction. Also antibody responses to bacteriophages and KLH can be inhibited by IgG administered 1-3 days after immunization with antigen. These observations suggest that the antigen must continuously interact with the immune system in order for a sustained IgM response to take place. Possibly, passively administered IgG interferes with this interaction and terminates the antibody response.

7 | IS IgG-MEDIATED SUPPRESSION DEPENDENT ON COMPLEMENT?

The Fc region of IgG is required for the ability to fix complement factor C1q (C1q) and activate the classical complement pathway. It is feasible that lysis of erythrocytes may render them less immunogenic than intact cells or that increased phagocytosis of IgG/complement-opsonized erythrocytes would make the antigen unavailable to B cells. Complement dependence of suppression has been addressed in a few studies. Monoclonal IgG1 antibodies, which could not activate complement, were efficient suppressors and IgG suppressed antibody responses to SRBC in C1q, C3 and CR1/CR2 knockout mice. In analogy, KEL-specific IgG suppressed IgG responses in C3 knockout mice immunized with KEL-RBC, although, as mentioned above, IgG could not suppress in mice lacking both C3 and activating FcγRs. In summary, the ability of IgG to activate complement cannot be the exclusive explanation for its ability to suppress antibody responses.

8 | IS IgG-MEDIATED SUPPRESSION EPITOPE SPECIFIC?

Suppression by IgG is antigen-specific in the sense that only responses to the antigen particle to which IgG binds are suppressed. This has been determined after administration to mice of IgG anti-SRBC + SRBC + horse red blood cells (HRBC), an antigen which does not cross react with SRBC. Such studies show that the response to HRBC is unperturbed while the response to SRBC is suppressed.

Whether IgG suppresses responses only to the epitope it binds to, or also to other epitopes on the same antigen, is an important question. Epitope specificity would indicate that, for example, epitope masking explains suppression while non-epitope specificity would indicate an Fc-dependent mechanism such as lysis, clearance or FcγRIIB-mediated inhibition of B-cell activation. However, both epitope-specific and non-epitope-specific suppression have been demonstrated and it has therefore been difficult to draw mechanistic conclusions from this type of experiments.

When we found that IgG suppressed efficiently in mice lacking all known FcγRs, suggesting Fc-independence, it became important to understand how non-epitope-specific suppression, suggesting Fc dependence, could take place. We hypothesized that the discrepant results regarding epitope specificity may be explained by taking epitope density into account (Figure 2). When IgG binds to an epitope present at low density, it would only suppress the antibody response to that epitope by masking it for B cells. The result would be epitope-specific suppression. When IgG binds to an epitope present at high density, it would suppress the antibody response both to that epitope and to neighbouring epitopes by stericly hindering B cells from accessing both types of epitopes. The result would be non-epitope-specific suppression. Experimental support for this hypothesis is that hapten-specific IgG, passively administered together with high- or low hapten density SRBC, suppressed the response.
against the hapten regardless of the epitope density but suppressed the response against SRBC determinants only when high hapten density SRBC was used as antigen. In line with this, suppression was epitope specific when murine erythrocytes, expressing both HOD and KEL, were used and it could be directly shown in superresolution microscopy that anti-KEL did not sterically hinder binding of anti-hen egg lysozyme (HEL) and vice versa.

The requirement for high epitope density in order for IgG to induce non-epitope-specific suppression is compatible with earlier experiments in which suppression of the entire antibody response to SRBC was studied. The ability of a panel of monoclonal SRBC-specific IgG antibodies to suppress SRBC responses correlated with their binding plateau to SRBC, and therefore with epitope density, and the ability of primary and secondary IgG to suppress correlated with their level of binding to SRBC. Moreover, a mixture of monoclonal IgG antibodies recognizing different epitopes on SRBC or on KEL-RBC was more suppressive than each monoclonal by itself, pointing to an additive effect.

With one exception, the observations discussed above concern suppression of IgM responses which has been studied in much greater detail than suppression of IgG responses. For unknown reasons, suppression of IgG responses appears to be epitope specific both when high and low density of NP-SRBC are used.

In summary, IgG-mediated suppression is antigen-specific, that is, only responses to the antigen to which IgG binds are suppressed. When IgG binds to an epitope present at low density, suppression is epitope specific. However, several lines of evidence suggest that when IgG binds to an epitope present at high density, it will suppress the response also to neighbouring epitopes. Therefore, the existence of non-epitope-specific suppression cannot be taken as evidence for Fc-dependent suppression.

9.1 Can FcγRIIB-mediated central inhibition of B cells explain IgG-mediated suppression?

The major hypotheses that have been proposed to explain the suppressive effect of IgG are (a) central inhibition of B-cell activation through co-crosslinking of BCR with the negatively regulating FcγRIIB by IgG-antigen complexes, (b) complement-mediated lysis of red blood cells, (c) increased clearance of IgG-antigen complexes, (d) masking of epitopes, preventing B cells from binding, and (e) trogocytosis, causing loss of IgG-bound epitopes, preventing B cells from binding. It cannot be excluded that several mechanisms contribute to suppression, but the discussion below will be based on the assumption that one single mechanism plays a dominant role.

**FIGURE 2** The importance of epitope density for specificity of suppression. When IgG binds to an epitope present at low density, only the epitopes to which IgG binds will be hidden from B cells while other epitopes will be available for B-cell recognition. This results in epitope-specific suppression (left). When IgG binds to an epitope present at high density, both the epitopes to which IgG binds and neighbouring epitopes will be hidden from B cells. This results in non-epitope-specific suppression (right). Modified from Xu, H. et al, Scientific Reports 2018, 8:15292.
of the BCR. This would lead to central inhibition of antigen-specific B cells because only cells with receptors for the antigen in question would be able to bind to the IgG-antigen complex and thus be downregulated (Figure 3). There is ample evidence that FcγRIIB indeed exerts a negative impact on many types of immune responses mediated via immunoreceptors which signal via ITAM (reviewed in Ref80). One example is the ‘enhanced enhancement’ of antibody responses to IgG-complexed proteins observed in FcγRIIB knockout mice.30,34 As mentioned in the introduction, IgG-mediated feedback enhancement operates via activating FcγRs, which signal via ITAM. In the absence of FcγRIIB, the enhancement is unregulated and becomes even more pronounced than in wildtype mice, thus demonstrating an in vivo effect of FcγRIIB.30,34

Nevertheless, negative regulation by FcγRIIB cannot explain feedback suppression by passively administered IgG. This is clearly shown by the unperturbed suppression of responses to SRBC38,52,74 or HOD-RBC47 in mice lacking FcγRIIB. These observations may seem paradoxical, given the well-documented negative regulatory effect of FcγRIIB, but become logical assuming that the role of this receptor is to downmodulate rather than to completely prevent a B-cell response. The initial studies of suppression in mice lacking FcγRIIB, activating FcγRs, or both, showed that IgG, administered in close temporal relation to SRBC or SRBC-TNP, suppressed the IgM anti-SRBC response equally well as in wildtype mice.38 This finding argued against the current paradigm stating that suppression was Fc-dependent, and it was suggested that the outcome would have been different under other experimental conditions. In a follow-up study, it was shown that IgG efficiently suppressed early IgG responses and secondary antibody responses in FcγRIIB knockout mice, and that IgG administered up to 4 days after SRBC suppressed equally well in FcγRIIB knockout and wildtype mice.52 Later, long-term IgG responses were also shown to be suppressed by IgG in FcγRIIB knockout mice.74

Monoclonal IgG3,36,37 IgE38,52 and IgM36 as well as polyclonal IgM7,62 can suppress antibody responses to SRBC. Neither IgG361 nor IgM binds to FcγRIIB. IgE has been reported to do so64 but suppresses well also in FcγRIIB knockout mice.65 Unless a different mechanism for suppression by IgG3, IgE and IgM than for suppression by IgG1, IgG2a and IgG2b is postulated, these observations argue against involvement of FcγRIIB in suppression.

In summary, there is no evidence supporting a role for FcγRIIB in IgG-mediated immune suppression of antibody responses to erythrocytes in vivo although the receptor negatively regulates other types of immune responses.

9.2 Can complement-mediated lysis of erythrocytes explain IgG-mediated suppression?

Most IgG subclasses can activate complement and activation of complement by IgG binding to erythrocyte surfaces may lead to haemolysis and thereby loss of immunogenicity (Figure 4). However, the ability of non-complement activating IgG to suppress60,76 and the efficient suppression in mice lacking either C1q74 or C344,74 suggest that suppression does not operate via lysis. Moreover, epitope specificity of suppression39-41,50,53,77 is hard to reconcile with lysis which would destroy the entire cell. The fact that IgG can suppress antibody response to viruses27,28 and
to proteins in adjuvants,\textsuperscript{25,26} which are not susceptible to haemolysis, also argues against a role of complement. In favour of a partial contribution of complement is the observation that suppression does not work in C3 $\times$ FcRγ double knockout mice immunized with KEL-RBC.\textsuperscript{44} Notably, suppression works well in single C3 knockout mice\textsuperscript{44} and IgG suppresses efficiently in C3 $\times$ FcRγ double knockout mice immunized with SRBC.\textsuperscript{75} In summary, a dominant role for complement-mediated lysis or complement-dependent clearance in IgG-mediated immune suppression seems unlikely.

### 9.3 | Can clearance/phagocytosis/relocalization of antigen explain IgG-mediated suppression?

Increased clearance of IgG-erythrocyte complexes has frequently been discussed as an explanation for IgG-mediated immune suppression. Elimination of erythrocytes from the circulation, and as a consequence from secondary lymphoid organs, would prevent recognition by specific B cells and result in a lack of antibody responses (Figure 5).

#### 9.3.1 | Xenogeneic erythrocytes and clearance

Xenogeneic erythrocytes, for example SRBC, administered intravenously are completely eliminated from the blood within ten minutes whether IgG is co-administered or not. Already after one minute, the levels of SRBC in the blood are similar in groups with and without passively administered IgG\textsuperscript{39} making it unlikely that IgG-mediated clearance is responsible for suppression in these experimental systems. The conclusion is strengthened by the observations that antibody responses can be suppressed when IgG is administered several days after SRBC,\textsuperscript{8,52,53,72,73} that is at a time point when no antigen remains in the circulation. Moreover, macrophages fed with IgG-SRBC and injected iv to mice induced a higher, rather than a lower, response than macrophages fed with SRBC alone.\textsuperscript{54}

Most likely, clearance induced by IgG would be dependent on FcγRs and/or complement. Therefore, the findings that IgG suppresses SRBC responses in mice lacking activating FcγRs,\textsuperscript{38,40,47,74} C1q or C3,\textsuperscript{74} or both C3 and activating FcγRs,\textsuperscript{75} argue against clearance as an important mechanism in this experimental system. The antibody response against intravenously administered SRBC is primarily initiated in the spleen and passively administered IgG has been shown to decrease the amount of SRBC in the marginal zone of wild-type mice.\textsuperscript{39,40} In FcRγ knockout mice, IgG did not decrease the amount of SRBC in the marginal zone, but nevertheless suppressed the antibody response to the same degree as in wildtype mice.\textsuperscript{40} This implies a lack of correlation between suppression and the ability of IgG to decrease clearance as detected by antigen localization to the spleen.

Epitope specificity of suppression\textsuperscript{39-41,53,77} is difficult to reconcile with clearance because the entire erythrocyte should be cleared and suppression/lack of response should affect all epitopes. Compatible with clearance as an explanation for IgG-mediated suppression are observations pointing to Fc dependence, such as lack of suppression by F(ab')\textsubscript{2} fragments\textsuperscript{36,42,56} and non-epitope specificity of suppression.\textsuperscript{36-39,41,42,46,48,76} However, as discussed elsewhere in this review, there may be alternative explanations for these findings.

#### 9.3.2 | Allogeneic erythrocytes and clearance

Because allogeneic erythrocytes persist much longer in the circulation than xenogeneic erythrocytes, the effects on clearance by IgG can be directly studied in these experimental systems. Also here, a number of observations argue against a major role for clearance. One example is experiments showing that three monoclonal IgG antibodies specific for HOD-RBC all suppressed the HEL-specific antibody response although none of them increased clearance.\textsuperscript{46} Efficient suppression in spite of poor clearance has also been reported.
with polyclonal IgG in allogeneic murine systems\(^{43,44,48,50}\) as well as with anti-RhD in humans.\(^{81-83}\)

In summary, the arguments against an exclusive role for clearance in IgG-mediated immune suppression are strong. There are many examples of efficient suppression in the total or partial absence of clearance, both in murine and human allogeneic systems. In xenogeneic systems, the strongest argument against clearance is that suppression works when IgG is administered several days after the antigen although erythrocytes are cleared from the circulation within minutes even without passive transfer of IgG. This does not exclude that clearance may have an additive effect to other mechanisms, at least when allogeneic erythrocytes are used.

9.4 | Can epitope masking explain IgG-mediated suppression?

Another hypothesis to explain IgG-mediated suppression is epitope masking. In this model, passively injected IgG would prevent antibody responses to antigen simply by hiding the epitopes from recognition by cognate B cells (Figure 6). This model relies only on the binding between antibody and antigen and would be independent of the Fc region of IgG. It is difficult to directly prove epitope masking and it remains primarily an ‘exclusion diagnosis’ relying on whether data are compatible with the hypothesis or not.

The fact that F(ab')\(_2\) fragments, IgM,\(^{7,36,62}\) and IgE\(^{38,63}\) can suppress is to be expected should masking of epitopes explain the phenomenon. Compatible with epitope masking is also the efficient suppression seen during conditions when IgG cannot activate complement\(^{60,76}\) or in the absence of C1q or C3\(^{44,74}\) or FcγRs.\(^{38,40,44,47,52,74}\) A strong argument in favour of epitope masking is the ability of IgG to suppress antibody responses to SRBC in double knockout mice lacking both C3 and activating FcγRs.\(^75\)

As would be predicted from the epitope masking model, specific T helper cell responses are normal in mice in which the antibody responses are efficiently suppressed by IgG.\(^{28,38,39,54}\) IgG, masking B-cell epitopes on the antigen surface, would not prevent the IgG-erythrocyte or IgG-virus complexes from being taken up and presented to T helper cells by antigen-presenting cells.

Two independent studies have shown that mice immunized with IgG anti-SRBC and SRBC produced antibodies to the Fc region of IgG but, as expected, not to SRBC.\(^{84,85}\) This is what would be anticipated should the passively administered IgG, bound to the SRBC surface, hide SRBC epitopes but present their Fc regions to B cells. Moreover, the additive suppressive effect of a blend of monoclonal antibodies specific for different epitopes on the erythrocyte fits with epitope masking\(^{37,78,79}\) as does the finding that suppression correlates with antibody affinity.\(^{36,60,67}\)

Epitope specificity of suppression\(^{39-41,53,77}\) is of course to be expected during epitope masking. As discussed above, also non-epitope-specific suppression may fit into the model provided that epitope density is considered.

While the above findings are all compatible with the epitope masking hypothesis, other findings are not. In studies using murine allogeneic erythrocytes as antigen, suppression was shown to occur in the apparent absence of epitope masking.\(^{46,48}\) Moreover, the inability of F(ab')\(_2\) fragments to suppress\(^{36,42,56}\) and the inability of immune serum to suppress responses to allogeneic erythrocytes in mice lacking both C3 and activating FcγRs\(^{44}\) are incompatible with epitope masking. However, for the latter observations discrepant findings have been reported: F(ab')\(_2\) sometimes suppresses\(^{26,38,47,69}\) and IgG can suppress responses to SRBC in C3 × FcγR double knockout mice.\(^75\)

In summary, many observations are compatible with the epitope masking hypothesis although conclusive experiments are lacking. Some observations are incompatible with epitope masking, but for several of them, either alternative explanations or conflicting results have been reported.

9.5 | Can trogocytosis (antigen modulation or antigen loss) explain IgG-mediated suppression?

Trogocytosis is a process through which cell membrane fragments are transferred from one cell to another after the two
cells have formed an immunologic synapse. Recently, this mechanism, also referred to as antigen modulation or antigen loss, has been suggested to explain IgG-mediated immune suppression in experimental systems using mouse allogeneic erythrocytes, expressing transgenic epitopes, as antigen. The idea is that IgG, binding to a certain epitope on an erythrocyte, induces removal of that epitope from the cell surface resulting in lack of an immune response (Figure 7). It has been shown by flow cytometry, and sometimes also by Western blot analysis, that the epitope to which the suppressing antibody bound was lost from the erythrocyte membrane. Mice do not have blood groups and do not produce antibodies against the allogeneic erythrocytes per se. Therefore, only responses against the transgenic epitopes, HOD or KEL, can be measured in these models. The mechanism behind trogocytosis is incompletely understood. In studies of IgG-induced antigen modulation, in which suppression of antibody responses was not analysed in parallel, modulation was either independent or dependent on FcγR receptors. Other studies showed dependence on C3 or suggested antigen-antibody crosslinking on the erythrocyte surface as the mechanism. When modulation and suppression were studied in parallel, both worked in the absence of either FcγRs or C3 but not in the simultaneous absence of both. The discrepant results concerning the mechanism behind trogocytosis make it difficult to relate to other observations of Fc dependence or independence of IgG-mediated immune suppression.

Epitope specificity has been studied also in the allogeneic models. Using mouse erythrocytes expressing both KEL and HOD, it was found that anti-KEL suppressed KEL- but not HEL-specific responses and anti-HEL suppressed HEL- but not KEL-specific responses. This suggested that suppression was epitope specific and it was shown by super resolution microscopy that anti-KEL antibodies did not sterically hinder the binding of anti-HEL to the HOD determinant and vice versa. Non-epitope-specific suppression has been described in experiments where anti-OVA suppressed the anti-HEL response to HOD-RBC. Possibly, these results may be explained by the close proximity of OVA, HEL and Duffy determinants on the transgenic epitope causing anti-OVA to modulate/remove all epitopes.

The observations described above are compatible with trogocytosis as the mechanism behind antibody-mediated suppression. Other findings are hard to fit into this model, such as suppression of antibody responses against viruses and proteins which do not have a cell membrane. The complete suppression of the antibody response against all epitopes on an erythrocyte is also difficult to understand in these terms, since it would require that the entire cell membrane is removed by trogocytosis. In some situations, both when xenogeneic and allogeneic erythrocytes were used, IgG suppressed the response to the specific epitope but enhanced the response to other epitopes on the same antigen. It is not clear how trogocytosis would accomplish this. These

**FIGURE 7** Trogocytosis/antigen modulation. Passively transferred IgG binds to its specific epitopes. This may lead to loss of these epitopes, possibly when phagocytes expressing FcγR recognize the IgG-erythrocyte complex and removes the IgG-bound epitopes.
observations may be better explained with epitope masking, where unmasked epitopes could be efficiently presented to T helper cells and induce an enhanced antibody response. As mentioned in the Introduction, IgG in complex with its antigen can feedback enhance T helper cell and antibody responses by increasing uptake and presentation of the antigen by antigen-presenting cells via their FcγRs. This has primarily been described for proteins, but may also affect erythrocyte epitopes which are not masked by IgG.

In summary, experiments using transgenic allogeneic erythrocytes as antigen have demonstrated that suppression of the antibody response to the transgenic epitope coincides with its disappearance from the erythrocyte surface. These observations suggest that trogocytosis is involved in IgG-mediated suppression. The mechanism behind trogocytosis is poorly understood and many basic questions are left to be solved such as the dependence on complement and FcγRs.

### CONCLUDING REMARKS

It has proven difficult to conclusively determine the mechanism(s) through which passively administered IgG suppresses the specific antibody response. In Table 1, a number of the experimental observations discussed above are listed. An attempt has been made to determine whether each of these can be fitted into the various hypotheses (columns 1-5) as well as whether they are compatible with dependence on the Fc region of IgG (column 6). Notably, the 'yes' and

#### TABLE 1

| Observations                                                                 | Inhibition by FcγRIIIB | CDC⁶ | Clearance/Phagocytosis | Epitope masking | Trogocytosis⁷ | IgG(Fc) is required |
|------------------------------------------------------------------------------|------------------------|------|------------------------|-----------------|---------------|--------------------|
| Epitope specificity             | NO                     | NO   | NO                     | Yes             | Yes           | NO                 |
| Non-epitope specificity         | Yes                    | Yes  | Yes                    | Yes             | Yes           | No                 |
| F(ab')2 can suppress            | NO                     | NO   | NO                     | Yes             | No            | No                 |
| F(ab')2 cannot suppress         | Yes                    | Yes  | Yes                    | No              | Yes           | Yes                |
| IgM can suppress                | NO                     | Yes  | Yes                    | Yes             | NO            | No                 |
| IgE can suppress                | NO                     | NO   | γe                      | Yes             | Yes           | No                 |
| Mouse IgG3 can suppress         | NO                     | Yes  | Yes                    | Yes             | Yes           | Yes                |
| High affinity IgG suppresses better than low⁸ | Yes | Yes | Yes                  | Yes             | Yes           | Yes                |
| Additive effect of mAb blends³⁹  | Yes                    | Yes  | γe                      | Yes             | Yes           | Yes                |
| Correlation between epitope density and suppression                         | Yes | Yes | γe                     | Yes             | Yes           | Yes                |
| Works in FcγRIIB KO             | NO                     | Yes  | Yes                    | Yes             | Yes           | No                 |
| Works in FcRγ KO                | Yes                    | Yes  | Yes                    | Yes             | NO            | No                 |
| Works in FcγRIIBxFcRγ dKO⁹       | NO                     | Yes  | Yes                    | Yes             | NO            | No                 |
| Works in FcRn KO                | Yes                    | Yes  | Yes                    | Yes             | Yes           | No                 |
| Works in C3 KO                  | Yes                    | NO   | Yes                    | Yes             | No            | No                 |
| Works in C1q KO                 | Yes                    | NO   | Yes                    | Yes             | No            | No                 |
| Non-C-activating IgG can suppress| YES                    | NO   | Yes                    | Yes             | Yes           | No                 |
| Works in (C3xFcγRγ) double KO⁴⁰ | Yes | NO | NO                     | Yes             | No            | No                 |
| Does not work in (C3xFcγRγ) double KO⁴⁰ | Yes | Yes | Yes                  | NO              | Yes           | Yes                |
| No correlation with clearance   | Yes                    | Yes  | NO                     | Yes             | Yes           | Yes                |
| IgG administered after Ag can suppress⁰ | Yes | NO | NO/yesf               | Yes             | γe          | NO/yesf            |
| Poor suppression of CD4+ T cells²⁸ | Yes | Yes | Yes                  | Yes             | Yes           | Yes                |

| Notes                  |
|-----------------------|
| a Complement-dependent cytotoxicity. |
| b Yes or NO is based on the assumption that trogocytosis depends on activating FcγRs, although this is not definitely proven. |
| c During high epitope density. |
| d Assuming that clearance is dependent on the IgG(Fc) region. |
| e Not sufficiently studied in this context for a yes or no. |
| f No: when Ag is rapidly eliminated (eg xenogeneic erythrocytes); Yes: when antigen remains for longer times in the circulation (eg allogeneic erythrocytes). |
XU AND HEYMAN

The remaining hypotheses are epitope masking and trogocytosis. In other words, does IgG suppress by hiding epitopes from B cells or by snatching epitopes from the erythrocytes thereby preventing B-cell recognition? There are few ‘no’s’ for either of these two hypotheses. Although the mechanism behind trogocytosis is not fully understood, we have assumed in the table that it is Fc-dependent. In the SRBC model, the experimental support for a major role of epitope masking is strong. Suppression works in the absence of (a) the Fc region of IgG (F(ab')2, IgE, IgM are suppressive), (b) FcRn, the inhibitory FcγRIIB, activating FcγRI, FcγRIII and FcγRIV, (c) both inhibitory and activating FcγRs, (d) C3, C1q, CR1/CR2, (e) both C3 and the activating FcγRI, FcγRIII and FcγRIV. Moreover, suppression is epitope specific, except when IgG binds to the SRBC surface at a high density when suppression of responses also to neighbouring epitopes can be seen. T helper cell induction is normal although the antibody responses are suppressed. There is a correlation between suppression and the amount of IgG bound to the SRBC surface. IgG administered several days after SRBC, when all antigen is cleared from the circulation, can suppress. An argument against epitope masking is the inability of F(ab')2 fragments to suppress, but the ability of IgG to suppress anti-SRBC responses in C3 × FcγRγ double knockout mice strongly supports that suppression is independent of the Fc region. To our knowledge, trogocytosis has not been investigated in the SRBC system, and it seems unlikely that the observed complete suppression of responses to all epitopes on the SRBC would be caused by this mechanism. In models using transgenic mouse erythrocytes, trogocytosis was proposed to explain IgG-mediated immune suppression from the observation that suppression coincided with loss of epitopes bound by the suppressive IgG. This hypothesis is quite recent and the mechanism behind IgG-induced trogocytosis is not yet well understood. Clearly, there are differences between how xenogeneic and allogeneic erythrocytes are handled by the immune system. The most important difference is probably the slower clearance of allogeneic erythrocytes than of xenogeneic erythrocytes. Another difference seems to be whether suppression operates in the simultaneous absence of both Fcγγ and C3. There are also similarities, such as the in-dependence of activating and inhibitory FcγRs or complement for suppression, found in all xenogeneic and some allogeneic studies. Also, more efficient suppression by a mixture of monoclonal antibodies than by each individual monoclonal is reported in both systems. Future studies will hopefully elucidate whether suppression of antibody responses to SRBC and to allogeneic erythrocytes is caused by different mechanisms or whether current differences can be explained by different experimental set-ups.

Determining how small amounts of IgG can completely suppress, or perhaps more correctly put, prevent, an antibody response is of great theoretical interest. It is also of practical importance. Rhesus prophylaxis currently relies on IgG antibodies obtained from polyclonal human sera. Understanding which qualities in an IgG antibody that are important for suppression would facilitate the search for clinically useful monoclonal IgG anti-RhD antibodies.

ACKNOWLEDGMENTS
We would like to thank our past and present colleagues who have been involved in the studies of IgG-mediated immune suppression over the years: Jessica Anania, Joakim JE Bergström, Imma Brogren, Teresita Diaz de Ståhl, Andrew Getahun, Susanne Gustavsson, Mikael CI Karlsson, Lars Pilström, Sara Wernersson, Annika Westin, Erik J. Wiersma and Lu Zhang. BH would also like to thank her former PhD supervisor, professor Hans Wigzell, for once proposing the fascinating project of antibody feedback regulation.

CONFLICT OF INTEREST
Authors declare no conflict of interest.

AUTHOR CONTRIBUTIONS
HX and BH wrote the manuscript and prepared the figures.

ORCID
Birgitta Heyman https://orcid.org/0000-0003-0869-0483

REFERENCES
1. Uhr JW, Möller G. Regulatory effect of antibody on the immune response. Adv Immunol. 1968;8:81-127.
2. Heyman B. Regulation of antibody responses via antibodies, complement, and Fc receptors. Annu Rev Immunol. 2000;18:709-737.
3. Nimmerjahn F, Ravetch JV. Antibody-mediated modulation of immune responses. Immuno Rev. 2010;236:265-275.
4. Heyman B. Antibody mediated regulation of humoral immunity. In: Nimmerjahn F, ed. Molecular and Cellular Mechanisms of
Antibody Activity. New York, NY: Springer Science+Business Media; 2013:221-248.
5. von Behring E, Wernerke E. Über Immunisierung und Heilung von Versuchstieren bei der Diphterie. Z Hyg Infektionskrankheit. 1892;12:10-44.
6. Smith T. Active immunity produced by so-called balanced or neutral mixtures of diphtheria toxin and antitoxin. J Exp Med. 1909;11:241-260.
7. Möller G, Wigzell H. Antibody synthesis at the cellular level. Antibody-induced suppression of 19S and 7S antibody responses. J Exp Med. 1965;121:969-989.
8. Wigzell H. Antibody synthesis at the cellular level. Antibody-induced suppression of 7S antibody synthesis. J Exp Med. 1966;124:953-969.
9. Henry C, Jerne N. Competition of 19S and 7S antigen receptors in the regulation of the primary immune response. J Exp Med. 1968;128:133-152.
10. Heyman B, Pilström L, Shulman MJ. Complement activation is required for IgM-mediated enhancement of the antibody response. J Exp Med. 1988;167:1999-2004.
11. Ding ZJ, Bergman A, Rutemark C, et al. Complement-activating IgM enhances the humoral but not the T cell immune response in mice. PLoS One. 2013;8(11):e81299.
12. Ferguson AR, Youd ME, Corley RB. Marginal zone B cells transport and deposit IgM-containing immune complexes onto follicular dendritic cells. Int Immunol. 2004;16:1411-1422.
13. Rutemark C, Bergman A, Getahun A, Hallgren J, Henningsson F, Heyman B. Complement receptors 1 and 2 in murine antibody responses to IgM-complexed and uncomplexed sheep erythrocytes. PLoS One. 2012;7(7):e41968.
14. Hjelm F, Karlsson MCI, Heyman B. A novel B-cell mediated transport of IgE-immune complexes to the follicle of the spleen. J Immunol. 2008;180:6604-6610.
15. Ding Z, Dahlin JS, Xu H, Heyman B. IgE-mediated enhancement of CD4+ T cell responses requires antigen presentation by CD8alpha(-) conventional dendritic cells. Sci Rep. 2016;6:28290.
16. Getahun A, Hjelm F, Heyman B. IgE enhances antibody and T cell responses in vivo via CD23(+) B Cells. J Immunol. 2005;175:1473-1482.
17. Carlsson F, Hjelm F, Conrad DH, Heyman B. IgE enhances specific antibody and T cell responses in mice overexpressing CD23. Scand J Immunol. 2007;66:261-270.
18. Heyman B, Liu T, Gustavsson S. In vivo enhancement of the specific antibody response via the low affinity receptor for IgE. Eur J Immunol. 1993;23:1739-1742.
19. Fujiwara H, Kikutani H, Suematsu S, et al. The absence of IgE antibody-mediated antigen uptake in vivo. Proc Natl Acad Sci USA. 1994;91:6835-6839.
20. Henningsson F, Ding Z, Dahlin JS, et al. IgE-mediated enhancement of CD4+ T cell responses in mice requires antigen presentation by CD11c+ cells and not by B cells. PLoS One. 2011;6:e21760.
21. Siegrist CA. Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants. Vaccine. 2003;21:3406-3412.
22. Clarke CA. Prevention of Rh-haemolytic disease. Br Med J. 1967;4:7-12.
23. Urbanik SJ, Greiss MA. RhD haemolytic disease of the fetus and the newborn. Blood Rev. 2000;14:44-61.
24. Cerottini JC, McConahey PJ, Dixon FJ. Specificity of the immunosuppression caused by passive administration of antibody. J Immunol. 1969;103:268-275.
25. Coulie P, Van Snick J. Enhancement of IgG anti-carrier responses by IgG2-anti-hapten antibodies in mice. Eur J Immunol. 1985;15:793-798.
26. Cerottini JC, McConahey PJ, Dixon FJ. The immunosuppressive effect of passively administered antibody IgG fragments. J Immunol. 1969;102:1008-1015.
27. Finkelstein MS, Uhr JW. Specific inhibition of antibody formation by passively administered 19S and 7S antibody. Science. 1964;146:67-69.
28. Vono M, Eberhardt CS, Auderset F, et al. Maternal antibodies inhibit neonatal and infant responses to vaccination by shaping the early-life B cell repertoire within germinal centers. Cell Rep. 2019;28:1773-1784 e5.
29. Hamano Y, Arase H, Saisho H, Saito T. Immune complex and Fc receptor-mediated augmentation of antigen presentation for in vivo Th cell responses. J Immunol. 2000;164:6113-6119.
30. Getahun A, Dahlström J, Wernersson S, Heyman B. IgG2a-mediated enhancement of antibody and T cell responses and its relation to inhibitory and activating Fc gamma receptors. J Immunol. 2004;172:5269-5276.
31. Diaz de Stahl T, Dahlström J, Carroll MC, Heyman B. A role for complement in feedback-enhancement of antibody responses by IgG3. J Exp Med. 2003;197:1183-1190.
32. Zhang L, Ding Z, Xu H, Heyman B. Marginal zone B cells transport IgG3-immune complexes to splenic follicles. J Immunol. 2014;193:1681-1689.
33. Zhang L, Ding Z, Heyman B. IgG3-antigen complexes are deposited on follicular dendritic cells in the presence of C1q and C3. Sci Rep. 2017;7:5400.
34. Wernersson S, Karlsson MC, Dahlström J, Mattsson R, Verbeek JS, Heyman B. IgG-mediated enhancement of antibody responses is low in Fc receptor gamma chain-deficient mice and increased in Fc gamma RI-deficient mice. J Immunol. 1999;163:618-622.
35. de Jong JM, Schuurhuis DH, Ioan-Facsinay A, et al. Dendritic cells, but not macrophages or B cells, activate major histocompatibility complex class II-restricted CD4+ T cells upon immune-complex uptake in vivo. Immunology. 2006;119:499-506.
36. Brüggemann M, Rajewsky K. Regulation of the antibody response against hapten-coupled erythrocytes by monoclonal anti-hapten antibodies of various isotypes. Cell Immunol. 1982;71:365-373.
37. Heyman B, Wigzell H. Immunoregulation by monoclonal sheep erythrocyte-specific IgG antibodies: suppression is correlated to level of antigen binding and not to isotype. J Immunol. 1984;132:1136-1143.
38. Karlsson MC, Wernersson S, Diaz de Stahl T, Gustavsson S, Heyman B. Efficient IgG-mediated suppression of primary antibody responses in Fcgamma receptor-deficient mice. Proc Natl Acad Sci USA. 1999;96:2244-2249.
39. Getahun A, Heyman B. Studies on the mechanism by which antigen-specific IgG suppresses primary antibody responses: evidence for epitope masking and decreased localization of antigen in the spleen. Scand J Immunol. 2009;70:277-287.
40. Bergström JJ, Xu H, Heyman B. Epitope-specific suppression of IgG responses by passively administered specific IgG: evidence of epitope masking. Front Immunol. 2017;8:238.
41. Xu H, Zhang L, Heyman B. IgG-mediated immune suppression in mice is epitope specific except during high epitope density conditions. Sci Rep. 2018;8:15292.
42. Enríquez-Rincon F, Klaus GGB. Differing effects of monoclonal anti-hapten antibodies on humoral responses to soluble or particulate antigens. Immunology. 1984;52:129-136.
43. Stowell SR, Arthur CM, Girard-Pierce KR, et al. Anti-KEL sera prevents alloimmunization to transfused KEL RBCs in a murine model. Haematologica. 2015;100:e394-e397.
44. Liu J, Santhanakrishnan M, Natarajan P, et al. Antigen modulation as a potential mechanism of anti-KEL immunophrophylaxis in mice. Blood. 2016;128:3159-3168.
45. Stowell SR, Liepkalns JS, Hendrickson JE, et al. Antigen modulation confers protection to red blood cells from antibody through Fcgamma receptor ligation. J Immunol. 2013;191:5013-5025.
46. Yu H, Stowell SR, Bernardo L, et al. Antibody-mediated immune suppression of erythrocyte alloimmunization can occur independently from red cell clearance or epitope masking in a murine model. J Immunol. 2014;193:2902-2910.
47. Bernardo L, Yu H, Amash A, Zimring JC, Lazarus AH. IgG-mediated immune suppression to erythrocytes by polyclonal antibodies can occur in the absence of activating or inhibitory Fc-gamma receptors in a full mouse model. J Immunol. 2015;195:2224-2230.
48. Cruz-Leal Y, Marjoram D, Lazarus AH. Erythrocyte saturation with IgG is required for inducing antibody-mediated immune suppression and impacts both erythrocyte clearance and antigen-modulation mechanisms. J Immunol. 2018;200:1295-1305.
49. Mener A, Patel SR, Arthur CM, Stowell SR. Antibody-mediated immunosuppression can result from RBC antigen loss independent of Fcgamma receptors in a mice. Transfusion. 2019;59:371-384.
50. Maier CL, Mener A, Patel SR, et al. Antibody-mediated immune suppression by antigen modulation is antigen-specific. Blood Adv. 2018;2:2986-3000.
51. Jerne NK, Nordin AA. Plaque formation in agar by single antibody-producing cells. Science. 1963;140:405.
52. Karlsson MC, Getahun A, Heyman B. FcgammaRIIB in IgG-mediated suppression of antibody responses: different impact in vivo and in vitro. J Immunol. 2001;167:5558-5564.
53. Möller G. Antibody-mediated suppression of the immune response is determinant specific. Eur J Immunol. 1985;15:409-412.
54. Brinc D, Le-Tien H, Crow AR, Freedman J, Lazarus AH. IgG-mediated immunosuppression is not dependent on erythrocyte clearance or immunological evasion: implications for the mechanism of action of anti-D in the prevention of haemolytic disease of the newborn? Br J Haematol. 2007;139:275-279.
55. Uhr JW, Baumann JB. Antibody formation. I. The suppression of antibody formation by passively administered antibody. J Exp Med. 1961;113:935-957.
56. Sinclair NRSC. Regulation of the immune response. I. Reduction in ability of specific antibody to inhibit longstanding IgG immunological priming after removal of the Fc fragment. J Exp Med. 1969;129:1183-1201.
57. Heyman B, Wizell H. Specific IgM enhances and IgG inhibits the induction of immunological memory in mice. Scand J Immunol. 1985;21:255-266.
58. Crowe JE Jr, Firestone CY, Murphy BR. Passively acquired antibodies suppress humoral but not cell-mediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines. J Immunol. 2001;167:3910-3918.
59. Gans HA, Maldonado Y, Yasukawa LL, et al. IL-12, IFN-gamma, and T cell proliferation to measles in immunized infants. J Immunol. 1999;162:5569-5575.
60. Wiersma EJ, Coulie PG, Heyman B. Dual immunoregulatory effects of monoclonal IgG-antibodies: suppression and enhancement of the antibody response. Scand J Immunol. 1989;29:439-448.
61. Gavin AL, Barnes N, Dijstelbloem HM, Hogarth PM. Identification of the mouse IgG3 receptor: Implications for antibody effector function at the interface between innate and adaptive immunity. J Immunol. 1998;160:20-23.
62. Wason WM. Regulation of the immune response with antigen specific IgM antibody: a dual role. J Immunol. 1973;110:1245-1252.
63. Karlsson MCI, Diaz de Ståhl T, Heyman B. IgE-mediated suppression of primary antibody responses in vivo. Scand J Immunol. 2001;53:381-385.
64. Takizawa F, Adamczewski M, Kinet J-P. Identification of the low affinity receptor for immunoglobulin E on mouse mast cells and macrophages as FcgRIII and FcgRII. J Exp Med. 1992;176:469-476.
65. Hirano M, Davis RS, Fine WD, et al. IgEb immune complexes activate macrophages through FcgammaRIIIB binding. Nat Immunol. 2007;8:762-771.
66. Mancardi DA, Iannascoli B, Hoos S, England P, Daeron M, Bruhns P. FcgammaRIIIB is a mouse IgE receptor that resembles macrophage FcEpislonRI in humans and promotes IgE-induced lung inflammation. J Clin Invest. 2008;118:3738-3750.
67. Walker JG, Siskind GW. Studies on the control of antibody synthesis. Effect of antibody affinity upon its ability to suppress antibody formation. Immunology. 1968;14:21-28.
68. Heyman B, Pilström L. Primary and secondary IgG antibodies are equally efficient immunsuppressors in relation to antigen binding capacity. Immunol Lett. 1988;17:189-194.
69. Tao TW, Uhr JW. Capacity of pepsin-digested antibody to inhibit antibody formation. Nature. 1966;212:208-209.
70. Junghans RP, Anderson CL. The protection receptor for IgG catabolism is the beta-2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci U S A. 1996;93:5512-5516.
71. Pollack W, Gorman JG, Freda VJ, Ascarlı WQ, Allen AE, Baker WJ. Results of clinical trials of RhO GAM in women. Transfusion. 1968:8:151-153.
72. Chan PL, Sinclair NR. Regulation of the immune response. VI. Inability of F(ab')2 antibody to terminate established immune responses and its ability to interfere with IgG antibody-mediated immunosuppression. Immunology. 1973;24:289-310.
73. Heyman B. Non-determinant specificity of feedback immunosuppression by IgG antibodies injected after the antigen. Scand J Immunol. 1988;27:361-365.
74. Bergström JJ, Heyman B. IgG suppresses antibody responses in mice lacking C1q, C3, complement receptors 1 and 2, or IgG Fc-receptors. PLoS One. 2015;10:e0143841.
75. Anania J, Westin A, Heyman B. IgG suppresses antibody responses to sheep red blood cells in double knock-out mice lacking complement factor C3 and activating Fcγ-receptors. Front Immunol. In press. https://doi.org/10.3389/fimmu.2020.01404
76. Heyman B, Wiersma E, Nose M. Complement activation is not required for IgG-mediated suppression of the antibody response. Eur J Immunol. 1988;18:1739-1743.
77. Brody NI, Walker JG, Siskind GW. Studies on the control of antibody synthesis. Interaction of antigenic competition and
suppression of antibody formation by passive antibody on the immune response. *J Exp Med.* 1967;126:81-91.

78. Quintana IZ, Silveira AV, Möller G. Regulation of the antibody response to sheep erythrocytes by monoclonal IgG antibodies. *Eur J Immunol.* 1987;17:1343-1349.

79. Bernardo L, Amash A, Marjoram D, Lazarus AH. Antibody-mediated immune suppression is improved when blends of anti-RBC monoclonal antibodies are used in mice. *Blood.* 2016;128:1076-1080.

80. Daëron M. Fc receptors as adaptive immunoreceptors. *Curr Top Microbiol Immunol.* 2014;382:131-164.

81. Lubenko A, Williams M, Johnson A, Pluck J, Armstrong D, MacLennan S. Monitoring the clearance of fetal RhD-positive red cells in FMH following RhD immunoglobulin administration. *Transfus Med.* 1999;9:331-335.

82. Miescher S, Spycher MO, Amstutz H, et al. A single recombinant anti-RhD IgG prevents RhD immunization: association of RhD-positive red blood cell clearance rate with polymorphisms in the FcgammaRIIA and FcgammaIIIA genes. *Blood.* 2004;103:4028-4035.

83. Beliard R. Monoclonal anti-D antibodies to prevent alloimmunization: lessons from clinical trials. *Transfus Clin Biol.* 2006;13:58-64.

84. Brinc D, Le-Tien H, Crow AR, Semple JW, Freedman J, Lazarus AH. Transfusion of antibody-opsonized red blood cells results in a shift in the immune response from the red blood cell to the antibody in a murine model. *Transfusion.* 2010;50:2016-2025.

85. Bergström JJE, Heyman B. Mice immunized with IgG anti-sheep red blood cells (SRBC) together with SRBC have a suppressed anti-SRBC antibody response but generate germinal centers and anti-IgG antibodies in response to the passively administered IgG. *Front Immunol.* 2017;8:911.

86. Joly E, Hadrisier D. What is trogocytosis and what is its purpose? *Nat Immunol.* 2003;4:815.

87. Taylor RP, Lindorfer MA. Fcgamma-receptor-mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments. *Blood.* 2015;125:762-766.

88. Zimring JC, Cadwell CM, Chadwick TE, et al. Nonhemolytic antigen loss from red blood cells requires cooperative binding of multiple antibodies recognizing different epitopes. *Blood.* 2007;110:2201-2208.

89. Mener A, Arthur CM, Patel SR, Liu J, Hendrickson JE, Stowell SR. Complement component 3 negatively regulates antibody response by modulation of red blood cell antigen. *Front Immunol.* 2018;9:676.

90. Zimring JC, Hair GA, Chadwick TE, et al. Nonhemolytic antibody-induced loss of erythrocyte surface antigen. *Blood.* 2005;106:1105-1112.

How to cite this article: Xu H, Heyman B. IgG-mediated suppression of antibody responses: Hiding or snatching epitopes?. *Scand J Immunol.* 2020;92:e12921. [https://doi.org/10.1111/sji.12921](https://doi.org/10.1111/sji.12921)